Cord Blood News 11.32 August 22, 2019 | |
| |
TOP STORYResearchers used decitabine, which is involved in the regulation of macrophage polarization, to test whether MSCs combined with decitabine could prolong and enhance the anti-diabetic effect in type 2 diabetes mice. [Stem Cell Res Ther] Full Article | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)The effect of human umbilical cord MSC-derived microvesicles on the restoration of ovarian function in a chemotherapy-induced premature ovarian insufficiency mouse model was investigated. [Stem Cell Res Ther] Full Article In this prospective single arm study, the authors evaluated the efficacy and safety of a novel consolidation therapy with low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion in elderly patients with acute myeloid leukemia. [BMC Cancer] Full Article Scientists explored the mechanism by which human umbilical cord blood MSC‐derived exosomes exerted a protective effect in hepatic ischemia/reperfusion injury. [IUBMB Life] Abstract Investigators prospectively collected clinical, laboratory, and technical collection data from hematopoietic stem cell collection procedures performed with the Spectra Optia apheresis system utilizing the continuous mononuclear collection protocol protocol. Data were compared to retrospectively collected data utilizing the mononuclear cell protocol. [J Clin Apher] Abstract Scientists used the Agilent 180 K human DNA methylation microarray on Wharton’s jelly (WJ)-MSCs, 5′azacytidine treated WJ-MSCs and human cardiac tissue to analyze differential DNA methylation profiles which were then validated by bisulfite sequencing PCR. [Genomics] Abstract Subscribe to one of our other 19 science newsletters such as Hematopoiesis News & Cell Therapy News. | |
| |
REVIEWSEngineering Universal Cells that Evade Immune Detection The prospect of transplanting cells and tissues without the risk of immune rejection or the need for powerful immunosuppressive drugs is the ‘holy grail’ of transplantation medicine. Now, with the advent of pluripotent stem cells, CRISPR-Cas9 and other gene-editing technologies, the race to create ‘off-the-shelf’ donor cells that are invisible to the immune system has started. [Nat Rev Immunol] Abstract Visit our reviews page to see a complete list of reviews in the cord blood research field. | |
| |
INDUSTRY NEWSPhio Pharmaceuticals Corp. announced that is has entered into a research collaboration with the Helmholtz Zentrum München. The agreement covers the design and development of new targets based on Phio Pharmaceuticals’ proprietary self-delivering RNAi platform for use in cancer immunotherapies. [Phio Pharmaceuticals Corp.] Press Release NKMax America Doses First Subject in Phase I Trial of SNK in Patients with Refractory Cancer NKMax America announced that it has dosed the first subject in study SNK01-US01, a Phase I clinical trial evaluating SNK, an ex vivo expanded autologous natural killer cell therapeutic, in patients with pathologically confirmed cancer refractory to conventional therapy. [NKMax America (PR Newswire Association LLC.)] Press Release | |
| |
POLICY NEWSMore Than 700 German Research Institutions Strike Open-Access Deal with Springer Nature A consortium of more than 700 German research institutions and libraries announced an agreement with publisher Springer Nature to make it simpler for authors to publish their papers open access. The agreement is the largest national open-access deal to date, but it doesn’t allow authors to publish open access in Nature or its sister journals. [ScienceInsider] Editorial As Brexit Nears, Britain’s Drugs, Devices and Pricing Regulators Seek the Exit Firm details on exactly how the UK will regulate new medicines is still to be decided after it leaves the EU later this year (caveats on timing abound), but we now know that the regulator won’t be run by Dr. Ian Hudson, who is stepping down after six years in charge. [FierceBiotech] Editorial Brazil’s Budget Cuts Threaten More Than 80,000 Science Scholarships Brazil’s main science-funding agency will have to suspend more than 80,000 scholarships to postdoctoral researchers and graduate and undergraduate students starting in September unless it receives additional cash from the government. [Nature News] Editorial
| |
EVENTSNEW Precision Health: Molecular Basis, Technology and Digital Health Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Studies – Normal and Aberrant Hematopoiesis (Karolinska Institutet) NEW Postdoctoral Scholarship – Human Erythropoiesis (Lund University) Scientific Communications Coordinator (STEMCELL Technologies Inc.) Postdoctoral Scholarship – Computational Genomics and Bioinformatics (Lund University) Postdoctoral Scholar – Gene and Cell Therapy (Stanford University) Associate Professor – Pediatrics (Pennsylvania State University) Early Stage Researchers – Hematopoiesis (Multiple Locations) PhD Positions – Age-Related Changes in Hematopoiesis (University of Milano-Bicocca) Postdoctoral Position – Bone/Stem Cell Biology (University of California, San Francisco) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cord Blood News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|